Abstract
Introduction: Egypt has the highest prevalence of (HCV) in the world. Interleukin 6 is a pleiotropic cytokine that increased in chronic hepatitis C patients. IL-6 was suggested by several studies to play a major role in response to HCV therapy Aim: The aim of this work was to assess the possible role of IL-6 on response status of patients with HCV during treatment. Also we try to use IL-6 as a predictive factor for response in patients with chronic HCV. Patients and Methods: Serum concentrations of Interleukin 6 (IL6) was measured before and after treatment using a commercially available Quantikine enzyme linked immunosorbent assay in fifty seven patients with chronic hepatitis C treated with sofosbuvir and simeprevir for 3 months. Results: The Mean values of IL6 level in responders and non-responders were 272.96 and 230.5 pg/mL respectively. IL-6 levels decrease significantly after treatment in SVR. the best cut-off point for IL6 was 233 pg/mL with a sensitivity of 70%, a specificity of 75% and a positive predictive value of 97.2%, negative predictive value of 16.7%. Conclusion: Virological response during HCV therapy was associated with decrease in IL-6 level.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Gastroenterology and Hepatology Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
